PharmaResearch Co Ltd banner
P

PharmaResearch Co Ltd
KOSDAQ:214450

Watchlist Manager
PharmaResearch Co Ltd
KOSDAQ:214450
Watchlist
Price: 320 500 KRW 1.1% Market Closed
Market Cap: ₩3.3T

PharmaResearch Co Ltd
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

PharmaResearch Co Ltd
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
P
PharmaResearch Co Ltd
KOSDAQ:214450
Research & Development
-₩30.1B
CAGR 3-Years
-54%
CAGR 5-Years
-40%
CAGR 10-Years
-34%
Celltrion Inc
KRX:068270
Research & Development
-₩218.9B
CAGR 3-Years
-91%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
O
OliX Pharmaceuticals Inc
KOSDAQ:226950
Research & Development
-₩20.9B
CAGR 3-Years
-2%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
V
Voronoi Inc
KOSDAQ:310210
Research & Development
-₩17.9B
CAGR 3-Years
-13%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Research & Development
-₩28.4B
CAGR 3-Years
-19%
CAGR 5-Years
-35%
CAGR 10-Years
-31%
A
ABL Bio Inc
KOSDAQ:298380
Research & Development
-₩95.6B
CAGR 3-Years
-35%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
No Stocks Found

PharmaResearch Co Ltd
Glance View

Market Cap
3.3T KRW
Industry
Biotechnology

In the competitive landscape of the biopharmaceutical industry, PharmaResearch Co Ltd. has carved a niche for itself by focusing on developing and commercializing cutting-edge regenerative medicine products. Rooted in South Korea, the company leverages its proprietary technologies to craft biotherapeutics that address unmet medical needs, primarily targeting chronic diseases and tissue repair. Central to its operations is their flagship product line based on platelet-rich plasma (PRP) technology, which has gained traction in the medical community for its efficacy in promoting healing and reducing recovery time. Through strategic partnerships and a robust R&D pipeline, PharmaResearch ensures its continued presence at the forefront of regenerative medicine. The company's revenue model is anchored in a multi-pronged approach that combines product sales, licensing agreements, and collaborative research ventures. By cultivating relationships with healthcare providers and hospitals, PharmaResearch supplies its innovative PRP kits and other regenerative solutions that are used in a variety of clinical settings, from orthopedic to dermatology practices. Furthermore, the company licenses its proprietary technologies to international partners, generating steady streams of royalties. By maintaining a strategic balance between domestic market penetration and global outreach, PharmaResearch Co Ltd. adeptly navigates the complexities of the biopharmaceutical sector while broadening its financial horizon.

PharmaResearch Co Ltd Intrinsic Value
HIDDEN
Show

See Also

What is PharmaResearch Co Ltd's Research & Development?
Research & Development
-30.1B KRW

Based on the financial report for Sep 30, 2025, PharmaResearch Co Ltd's Research & Development amounts to -30.1B KRW.

What is PharmaResearch Co Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-34%

Over the last year, the Research & Development growth was -51%. The average annual Research & Development growth rates for PharmaResearch Co Ltd have been -54% over the past three years , -40% over the past five years , and -34% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett